Praxis Precision Medicines Inc. (PRAX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Praxis Precision Medicines (PRAX) Upgraded to Buy: What Does It Mean for the Stock?
Praxis Precision Medicines (PRAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Praxis Precision Medicines, Inc. (PRAX) Q2 2024 Earnings and Corporate Update Call Transcript
Praxis Precision Medicines, Inc. (NASDAQ:PRAX ) Q2 2024 Earnings Conference Call August 13, 2024 8:00 AM ET Company Participants Marcio Souza - President and Chief Executive Officer Tim Kelly - Chief Financial Officer Daniel Ferry - Investor Relations, Life Science Advisors Conference Call Participants Yasmeen Rahimi - Piper Sandler Joon Lee - Truist Securities Francois Brisebois - Oppenheimer Yatin Suneja - Guggenheim Ritu Baral - TD Cowan Joel Beatty - Baird Ami Fadia - Needham Douglas Tsao - HC Wainwright & Co Kambiz Yazdi - Jeffries Operator Good day, thank you for standing by. Welcome to the Praxis Precision Medicines' Second Quarter 2024 Corporate Update Conference Call.
Praxis Precision Medicines, Inc. (PRAX) Reports Q2 Loss, Lags Revenue Estimates
Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $1.74 per share versus the Zacks Consensus Estimate of a loss of $2.38. This compares to loss of $7.35 per share a year ago.
Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?
Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
